22
Introduction: 41Malaria remains one of the great global health problems today, taking a large toll on people in the 42 tropics and subtropics. This disease, caused by Plasmodium parasites, affects over 200 million people 43 annually and kills over 400,000 (WHO World Malaria Report 2018). While a protein-based subunit 44 vaccine (RTS,S) has recently been licensed and is being used for pilot implementation in three Saharan African countries, its protection has been limited and relatively short-lived in clinical trials 1 . 46 Identifying and fully testing an effective and long-lasting malaria vaccine remains a chief goal that has 47 yet to be achieved. Accomplishing this will require greater knowledge of the basic biology of the pre-48 erythrocytic sporozoite and liver stage parasites. Promising new whole-parasite vaccine candidates, 49 based upon the sporozoite form of the parasite, are on the horizon and hopefully will meet these needs 50 2 . 51Plasmodium parasites are transmitted between hosts by an infected female Anopheles mosquito 52 (reviewed in 3 ). Following uptake of male and female gametocytes by the mosquito during a blood meal 53 of an infected host, these parasites activate into male and female gametes in the midgut, fuse into a 54 zygote, and develop into a motile ookinete, which burrows through the midgut wall and establishes an 55 oocyst under the basal lamina. Within the oocyst, the parasite undergoes sporogony to produce up to 56 five thousand oocyst sporozoites 4 . These oocyst sporozoites are weakly infectious if injected directly 57 into a naïve mammalian host 5 , but become highly infectious following proteolytic rupture of the oocyst 58 wall and transit through the mosquito hemocoel. Sporozoites further gain infectivity after invasion of 59 the salivary glands 5,6 . Interestingly, the gain of infectivity for the mammalian host is concomitant with a 60 loss of infectivity for the salivary glands. Within the glands, the sporozoites await transmission as 61 salivary gland sporozoites, which occurs when the mosquito takes its next blood meal. Infection of a 62 host begins with the injection of salivary gland sporozoites into the skin. Following this, sporozoites exit 63 the bite site in the skin, locate and enter the vasculature, and passively travel to the liver, where 64 sporozoites can productively infect hepatocytes, which initiates the life cycle progression in the 65 mammalian host 7 . Moreover, because relatively few sporozoites are injected during a mosquito bite 8 , 66 this transmission event bottleneck has been the focus of intervention efforts using drugs, subunit 67 vaccines, and attenuated whole parasite vaccines 2 . 68Fundamental studies of sporozoite biology have informed efforts to inhibit and/or arrest the parasite 69 during development. To date, genetically-attenuated parasite (GAP) vaccine candidates were generated 70 by the deletion of genes whose transcripts are Up-regulated in Infective (Salivary Gland) Sporozoites 71 (UIS). The UIS gene family was originally determi...